An evaluation of subcutaneous apomorphine for the treatment of Parkinson’s disease

References

• Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol. 2003;54:403–414.
   PubMed Web of Science ®Google Scholar
• Henchcliffe C, Sarva H. Restoring function to dopaminergic neurons: progress in the development of cell-based therapies for Parkinson’s Disease. CNS Drugs. 2020; Epub. DOI:10.1007/s40263-020-00727-3.
   PubMed Web of Science ®Google Scholar
• Zygogianni O, Kouroupi G, Taoufik E, et al. Engraftable induced pluripotent stem cell-derived neural precursors for brain repair. Methods Mol Biol. 2020;2155:23–39.
   PubMedGoogle Scholar
• Schweitzer JS, Song B, Herrington TM, et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson’s Disease. N Engl J Med. 2020;382:1926–1932.
   PubMed Web of Science ®Google Scholar
• Shihabuddin LS, Brundin P, Greenamyre JT, et al. New frontiers in Parkinson’s disease: from genetics to the clinic. J Neurosci. 2018;38:9375–9382.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Standaert DG, Kieburtz K, et al. Once-weekly subcutaneous delivery of polymer-linked rotigotine (SER-214) provides continuous plasma levels in Parkinson’s disease patients. Mov Disord. 2020. Epub. DOI:10.1002/mds.28027
   PubMed Web of Science ®Google Scholar
• Olanow CW, Factor SA, Espay AJ, et al. Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020;19:135–144.
   PubMed Web of Science ®Google Scholar
• Ramot Y, Nyska A, Maronpot RR, et al. Ninety-day local tolerability and toxicity Study of ND0612, a novel formulation of levodopa/ carbidopa, administered by subcutaneous continuous infusion in minipigs. Toxicol Pathol. 2017;45:764–773.
   PubMed Web of Science ®Google Scholar
• Ramot Y, Nyska A, Adar L, et al. ND0701, A novel formulation of apomorphine for subcutaneous infusion, in comparison to a commercial apomorphine formulation: 28-Day pharmacokinetic study in minipigs and a Phase I study in healthy volunteers to assess the safety, tolerability, pharmacokinetics and relative bioavailability. CNS Drugs. 2018;32:443–454.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Tanner CM, Hauser RA, et al. ADS-5102 (Amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID Study): a randomized clinical trial. JAMA Neurol. 2017;74:941–949.
   PubMed Web of Science ®Google Scholar
• Aquilonius SM, Nyholm D. Development of new levodopa treatment strategies in Parkinson’s disease-from bedside to bench to bedside. Ups J Med Sci. 2017;122:71–77.
   PubMed Web of Science ®Google Scholar
• Calabresi P, Di FM, Ghiglieri V, et al. Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gap. Lancet Neurol. 2010;9:1106–1117.
   PubMed Web of Science ®Google Scholar
• Kianirad Y, Simuni T. Novel approaches to optimization of levodopa therapy for Parkinson’s disease. Curr Neurol Neurosci Rep. 2016;16:34–44.
   PubMed Web of Science ®Google Scholar
• Chen C, Cowles VE, Sweeney M, et al. Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease. Clin Neuropharmacol. 2012;35:67–72.
   PubMed Web of Science ®Google Scholar
• Dorozynski P, Kulinowski P, Mendyk A, et al. Gastroretentive drug delivery systems with L-dopa based on carrageenans and hydroxypropylmethylcellulose. Int J Pharm. 2011;404:169–175.
   PubMed Web of Science ®Google Scholar
• Freitas ME, Ruiz-Lopez M, Fox SH. Novel levodopa formulations for Parkinson’s disease. CNS Drugs. 2016;30:1079–1095.
   PubMed Web of Science ®Google Scholar
• Klausner EA, Lavy E, Barta M, et al. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans. Pharm Res. 2003;20:1466–1473.
   PubMed Web of Science ®Google Scholar
• Verhagen ML, Stover N, Chen C, et al. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson’s disease. Mov Disord. 2015;30:1222–1228.
   PubMedGoogle Scholar
• Senek M, Nyholm D. Continuous drug delivery in Parkinson’s disease. CNS Drugs. 2014;28:19–27.
   PubMed Web of Science ®Google Scholar
• Klostermann F, Jugel C, Bomelburg M, et al. Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion. Mov Disord. 2012;27(13):1704–1705.
   PubMed Web of Science ®Google Scholar
• Klostermann F, Jugel C, Müller T, et al. Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm (Vienna). 2012;119:369–372.
   PubMed Web of Science ®Google Scholar
• Jenner P, Katzenschlager R. Apomorphine - pharmacological properties and clinical trials in Parkinson’s disease. Parkinsonism Relat Disord. 2016;33(Suppl 1):S13–S21.
   PubMedGoogle Scholar
• Ekesbo A, Rydin E, Torstenson R, et al. Dopamine autoreceptor function is lost in advanced Parkinson’s disease. Neurology. 1999;52:120–125.
   PubMed Web of Science ®Google Scholar
• Henriksen T. Clinical insights into use of apomorphine in Parkinson’s disease: tools for clinicians. Neurodegener Dis Manag. 2014;4:271–282.
   PubMedGoogle Scholar
• Nomoto M, Kubo S, Nagai M, et al. A randomized controlled trial of subcutaneous apomorphine for Parkinson disease: a repeat dose and pharmacokinetic study. Clin Neuropharmacol. 2015;38:241–247.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Chaudhuri KR, Garcia Ruiz PJ, et al. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson’s disease–Clinical practice recommendations. Parkinsonism Relat Disord. 2015;21:1023–1030.
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Chaudhuri KR, LeWitt P, et al. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses. Clin Neuropharmacol. 2015;38:89–103.
   PubMed Web of Science ®Google Scholar
• Borgemeester RWK, van LT, Schuttelaar MLA. Cutaneous adverse drug reaction after apomorphine infusion, possibly caused by a systemic type IV hypersensitivity reaction to sodium metabisulfite: report of 2 cases. Contact Dermatitis. 2018;79:316–318.
   PubMed Web of Science ®Google Scholar
• Priano L, Albani G, Calderoni S, et al. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson’s disease. Neurol Sci. 2002;23(Suppl 2):S99–100.
   PubMedGoogle Scholar
• Hauser RA, Olanow CW, Dzyngel B, et al. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson’s disease. Mov Disord. 2016;31:1366–1372.
   PubMed Web of Science ®Google Scholar
• Borgemeester RW, Drent M, van LT. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson’s disease patients. Parkinsonism Relat Disord. 2016;23:17–22.
   PubMed Web of Science ®Google Scholar
• Garcia Ruiz PJ, Sesar IA, Ares PB, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord. 2008;23:1130–1136.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Koller WC, Trosch RM, et al. Subcutaneous apomorphine in patients with advanced Parkinson’s disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci. 2007;258:137–143.
   PubMed Web of Science ®Google Scholar
• Gervason CL, Pollak PR, Limousin P, et al. Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson’s disease. Clin Neuropharmacol. 1993;16:113–119.
   PubMed Web of Science ®Google Scholar
• Trosch RM, Silver D, Bottini PB. Intermittent subcutaneous apomorphine therapy for ‘off’ episodes in Parkinson’s disease: a 6-month open-label study. CNS Drugs. 2008;22:519–527.
   PubMed Web of Science ®Google Scholar
• van LT, Jansen EN, Essink AW, et al. A double-blind study of the efficacy of apomorphine and its assessment in ‘off’-periods in Parkinson’s disease. Clin Neurol Neurosurg. 1993;95:231–235.
   PubMed Web of Science ®Google Scholar
• Grosset KA, Malek N, Morgan F, et al. Inhaled apomorphine in patients with ‘on-off’ fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study. J Parkinsons Dis. 2013;3:31–37.
   PubMedGoogle Scholar
• Grosset KA, Malek N, Morgan F, et al. Inhaled dry powder apomorphine (VR040) for ‘off‘ periods in Parkinson’s disease: an in-clinic double-blind dose ranging study. Acta Neurol Scand. 2013;128:166–171.
   PubMed Web of Science ®Google Scholar
• Grosset KA, Malek N, Morgan F, et al. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing ‘off’ periods in patients with established Parkinson’s disease. Eur J Neurol. 2013;20:1445–1450.
   PubMed Web of Science ®Google Scholar
• Borgemeester RWK, van LT. Continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with cognitive dysfunction: A retrospective long-term follow-up study. Parkinsonism Relat Disord. 2017;45:33–38.
   PubMed Web of Science ®Google Scholar
• Dafsari HS, Martinez-Martin P, Rizos A, et al. EuroInf 2: subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson’s disease. Mov Disord. 2019;34:353–365.
   PubMed Web of Science ®Google Scholar
• Dewey RB Jr., Hutton JT, Lewitt PA, et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58:1385–1392.
   PubMed Web of Science ®Google Scholar
• Drapier S, Eusebio A, Degos B, et al. Quality of life in Parkinson’s disease improved by apomorphine pump: the OPTIPUMP cohort study. J Neurol. 2016;263:1111–1119.
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson’s disease: response to chronic administration for up to five years. Mov Disord. 1993;8:165–170.
   PubMed Web of Science ®Google Scholar
• Isaacson S, Lew M, Ondo W, et al. Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson’s Disease. Mov Disord Clin Pract. 2017;4:78–83.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Reddy P, Antonini A, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson’s disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis. 2011;1:197–203.
   PubMedGoogle Scholar
• Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord. 2015;30:510–516.
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17:749–759.
   PubMed Web of Science ®Google Scholar
• Todorova A, Ray CK. Subcutaneous apomorphine and non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2013;19:1073–1078.
   PubMed Web of Science ®Google Scholar
• Fernandez-Pajarin G, Sesar A, Ares B, et al. Evaluating the efficacy of nocturnal continuous subcutaneous apomorphine infusion in sleep disorders in advanced Parkinson’s disease: the APO-NIGHT study. J Parkinsons Dis. 2016;6:787–792.
   PubMedGoogle Scholar
• Merello M, Pikielny R, Cammarota A, et al. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson’s disease patients: a double-blind single-dose study. Clin Neuropharmacol. 1997;20:165–167.
   PubMed Web of Science ®Google Scholar
• Lipp MM, Batycky R, Moore J, et al. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson’s disease. Sci Transl Med. 2016;8:360ra136.
   PubMed Web of Science ®Google Scholar
• Luinstra M, Grasmeijer F, Hagedoorn P, et al. A levodopa dry powder inhaler for the treatment of Parkinson’s disease patients in off periods. Eur J Pharm Biopharm. 2015;97:22–29.
   PubMed Web of Science ®Google Scholar
• Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Mov Disord. 2002;17:1235–1241.
   PubMed Web of Science ®Google Scholar
• Titova N, Chaudhuri KR. Personalized medicine and nonmotor symptoms in Parkinson’s DISEASE. Int Rev Neurobiol. 2017;134:1257–1281.
   PubMed Web of Science ®Google Scholar
• Müller T, Öhm G, Eilert K, et al. Benefit on motor and non-motor behavior in a specialized unit for Parkinson’s disease. J Neural Transm (Vienna). 2017;124:715–720.
   PubMed Web of Science ®Google Scholar
• Titova N, Chaudhuri KR. Personalized medicine in Parkinson’s disease: time to be precise. Mov Disord. 2017;32:1147–1154.
   PubMed Web of Science ®Google Scholar
• Ng Ying Kin NM, Lal S, Thavundayil JX. Stability of apomorphine hydrochloride in aqueous sodium bisulphite solutions. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:1461–1468.
   PubMed Web of Science ®Google Scholar
• Avis TJ, Michaud M, Tweddell RJ. Role of lipid composition and lipid peroxidation in the sensitivity of fungal plant pathogens to aluminum chloride and sodium metabisulfite. Appl Environ Microbiol. 2007;73:2820–2824.
   PubMed Web of Science ®Google Scholar
• Ercan S, Kencebay C, Basaranlar G, et al. Induction of omega 6 inflammatory pathway by sodium metabisulfite in rat liver and its attenuation by ghrelin. Lipids Health Dis. 2015;14:7.
   PubMed Web of Science ®Google Scholar
• Garcia-Gavin J, Parente J, Goossens A. Allergic contact dermatitis caused by sodium metabisulfite: a challenging allergen: a case series and literature review. Contact Dermatitis. 2012;67:260–269.
   PubMed Web of Science ®Google Scholar
• Garabatos-Perera J Stable apomorphine composition and uses there of.; PCT/US2015/024616. 2015: 1–17
   Google Scholar
• Bilbault T, Taylor S, Walker R, et al. Buccal mucosal irritation studies of sublingual apomorphine film (APL-130277) in Syrian golden hamsters. Ther Deliv. 2016;7:611–618.
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Rascol O, Senard JM, et al. Sublingual apomorphine in Parkinson’s disease: a clinical and pharmacokinetic study. Clin Neuropharmacol. 1991;14:432–437.
   PubMed Web of Science ®Google Scholar
• Durif F, Deffond D, Tournilhac M. Efficacy of sublingual apomorphine in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1990;53:1105.
   PubMed Web of Science ®Google Scholar
• Lewitt PA, Hauser RA, Pahwa R, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019;18:145–154.
   PubMed Web of Science ®Google Scholar
• Luinstra M, Rutgers W, van LT, et al. Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson’s disease. Ther Adv Chronic Dis. 2019;10:2040622319857617.
   Web of Science ®Google Scholar
• Lewitt PA, Huff FJ, Hauser RA, et al. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson’s disease. Mov Disord. 2014;29:75–82.
   PubMed Web of Science ®Google Scholar
• Müller T, Benz S, Börnke C, et al. Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson’s disease. J Neural Transm (Vienna). 2003;110:603–609.
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Werdelin L, Odin P, et al. Pen injected apomorphine against off phenomena in late Parkinson’s disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1995;58:681–687.
   PubMed Web of Science ®Google Scholar
• Stibe CM, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet. 1988;1:403–406.
   PubMed Web of Science ®Google Scholar